Rationale: Proangiogenic hematopoietic and endothelial progenitor cells (EPCs) contribute to postnatal neovascularization, but the mechanisms regulating differentiation to the endothelial lineage are unclear.
endothelial gene activation and unique combinational regulation of multiple transcription factors is required for endothelial specification and differentiation. However, many of these transcription factors implicated in vasculogenesis are also expressed in nonendothelial cells like hematopoietic stem cells but are not sufficient to activate endothelial genes. 3 Likewise, expression of the prototypical gene endothelial NO synthase (eNOS) is controlled by a variety of transcription factors such as Sp-1, Ets-1, and YY1, but these transcription factors are also expressed in nonendothelial cells. These observations have led to the hypothesis that additional mechanisms including chromatin modifications might regulate the accessibility of transcription factors and thereby control endothelial lineage commitment.
Gene expression is regulated by chromatin-based epigenetic pathways, which include DNA methylation and covalent modification of histones. Methylation of DNA occurs at cytosine residues in CpG dinucleotides (CpGs) and is catalyzed by DNA methyltransferases. DNA methylation is essential in mammalian development for the repression of imprinted genes and for X-chromosome inactivation. 4 The N-terminal tails of histones are subject to various posttranslational modifications such as acetylation, methylation, phosphorylation, ubiqitination, and sumoylation. 5 In general, acetylation of histone H3 and H4 is associated with increased gene expression and was shown to regulate the angiogenic function of endothelial cells. 6 The effect of histone methylation on transcription depends on the specific lysine (K) residues and degree of methylation (mono-, di-, or trimethylation), attached to the specific sites. Histone H3 modification at K4 and K36 is associated with activation of gene expression, whereas the effect of K9 methylation depends on the location of the mark. Methylation of the lysine residue 27 (K27) is involved in epigenetic silencing of gene expression and is tightly controlled by the Polycomb group proteins such as the enhancer of zest homolog 2 (Ezh2), a histone methyltransferase that can trimethylate H3K27. The presence of H3K27me3 at transcription start sites is correlated with repression of gene expression. H3K27me3 has initially been considered as an irreversible silencing mark; however, several recent studies suggested reversibility by the JmjC domain-containing proteins Jmjd3 and UTX as genuine H3K27 demethylases. 7 The reversion of H3K27me3 silencing marks by Jmjd3/UTX has been implicated in proper activation of HOX genes, anterior-posterior identity, inflammationinduced macrophage activation, and differentiation of mammalian tissues. 7, 8 We and others have demonstrated that administration of bone marrow mononuclear cells or cultured early endothelial progenitor cells (EPCs), which express the myeloid markers CD14 and CD45, improved the functional recovery after ischemia in experimental models of hind limb and myocardial ischemia and modestly augmented the ejection fraction in patients with acute myocardial infarction. 9,10 Mechanistically, we have shown that eNOS is essential for progenitor cells mobilization and function 11 and that increasing eNOS expres-sion by eNOS enhancers improved functional activity of patient-derived cells. Recent data demonstrated that particularly eNOS expressing cells contribute to the maintenance of functional recovery after ischemia when using lineagecommitted suicide vectors to deplete bone marrow mononuclear cells 2 weeks after injection in a myocardial infarction model. 12 Together, these data suggest that eNOS expression is important for the functional effects achieved by administration of progenitor cells for the treatment of ischemia.
Here, we aim to elucidate the epigenetic control of endothelial gene expression in cultured EPCs (early EPCs, now termed proangiogenic cells [PACs] because of the coexpression of hematopoietic markers), isolated CD34 ϩ cells, and mesoangioblasts. Based on preliminary findings that hypoxia and inflammation enhance the expression of epigenetic regulators of gene expression, we hypothesize that, under conditions of severe stress, the epigenetic profile of cells is modulated, thereby facilitating endothelial commitment. Using the eNOS as a prototypic endothelial gene, we demonstrate that the eNOS promoter is characterized by a profound DNA methylation and repressive trimethylation of histone H3 at lysine 27 in CD34 ϩ cells and cultured PACs. Pharmacological inhibition of silencing histone H3K27me3 marks in combination with induction of histone acetylation by histone deacetylase inhibitors augmented the expression of eNOS. Most importantly, we demonstrate that hypoxia increased the expression of the histone demethylase Jmjd3 and partially reversed the repression of the endothelial genes.
Methods
Experimental protocols are described in the Supplemental Methods section, available online at http://circres.ahajournals.org.
Results

DNA Methylation Status of the 5-Flanking Region of the Human eNOS Gene
DNA methylation controls the expression of eNOS gene. 13 To determine the epigenetic state of endothelial commitment at the level of DNA methylation, we analyzed DNA methylation of the eNOS promoter region 800 bases upstream of the transcription start site, which spans the proximal promoter that controls basal eNOS expression 3 by bisulfite genomic DNA sequencing ( Figure 1A ). Whereas the proximal eNOS promoter was either devoid of or very lightly methylated in differentiated human endothelial cell types including human umbilical vein endothelial cell (HUVEC) and microvascular endothelial cell, the promoter was heavily methylated in all examined proangiogenic cells such as peripheral bloodderived PACs (ϭearly EPCs), bone marrow-derived CD34 ϩ hematopoietic progenitor cells, and mesoangioblasts, which are isolated from peripheral blood and express mesenchymal and endothelial markers 14 ( Figure 1A ). Because cultured PACs and CD34 ϩ cells comprise a heterogeneous cell population and contaminations might have affected our results, we additionally isolated the subpopulation of CD34 ϩ cells that coexpressed the endothelial marker KDR ( Figure 1B) . Although KDR is also expressed in stem cells, the CD34 ϩ KDR ϩ population was assumed to be enriched in EPCs. However, isolated CD34 ϩ KDR ϩ cells also did show a hypermethylated status of the eNOS promoter ( Figure 1B ). 13 Collectively, these results revealed that the eNOS promoter is highly methylated irrespective of the progenitor cell subpopulation studied, suggesting a limited commitment of the cells toward the endothelial lineage under steady state conditions.
Non-standard Abbreviations and Acronyms
Histone Methylation Status of the Human eNOS Promoter
Besides gene repression by DNA methylation, posttranslational modifications of histone N-terminal tails are dynamic and essential components in the epigenetic regulation of genes. 15 Therefore, using a quantitative chromatin immunoprecipitation (ChIP) technique, we examined post- 
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translational histone modifications at the eNOS promoter in cultured PACs, CD34 ϩ cells, and HUVEC. Histone modifications were specifically detected in regions of the eNOS promoter, which were shown to control eNOS gene expression such as positive regulatory domains I (Ϫ104/ Ϫ95) and II (Ϫ144/Ϫ115), the redox-sensitive-AP-1 binding site (Ϫ662/Ϫ656), TGF-␤ activating Smad2 binding site (Ϫ1000/Ϫ720), and the hypoxia-responsive element site (Ϫ5375/Ϫ5366) that are thought to be important for hypoxia-induced transcription of eNOS (Figure 2A , Supplemental Material). We observed that the repressive H3K27me3 mark was highly enriched at all sites studied in PACs, whereas another repressive histone modification, H3K9me3, was rather low (Figure 2A ). Some progenitor cells are reported to display "bivalent" domains, which are characterized by H3K4me3 and H3K27me3 marks. However, almost no enrichment of active H3K4me3 marks was observed at the eNOS promoter in PACs, and acetylation of histone H3 was only modest (Figure 2A ). Similar results were obtained in CD34 ϩ cells (Figure 2A ). Again, the repressive H3K27me3 mark was enriched at the eNOS promoter, whereas the active H3K4me3 was absent and histone H3 acetylation was only slightly elevated. In contrast, in endothelial cells (HUVEC), only active (histone H3 acetylation and H3K4me3) marks were detected ( Figure 2A ). However, at the 5Ј region of the eNOS promoter (Ϫ9730/Ϫ9670), which lacks endothelial transcription factor binding sites, we observed that high levels of repressive histone modifications (H3K27me3 and H3K9me3) were dominant also in HUVEC demonstrating that the lack of repressive marks in the regulatory regions of the eNOS promoter in HUVEC is not due to a failure of the ChIP experiment (Supplemental Figure I) . These results indicate that the eNOS promoter is epigenetically silenced by H3K27me3 marks in PACs and CD34 ϩ cells compared to HUVEC. The prevalence of DNA methylation and repressive histone marks at the eNOS promoter in PACs and CD34 ϩ cells correlate closely with a low eNOS mRNA expression levels in these cells compared to HUVEC ( Figure 2B ). 
Histone Methylation Status of the Promoters of Other Endothelial Genes
To determine whether the repression of endothelial genes in proangiogenic cell subtypes is specific for eNOS or extends to other endothelial committed genes, we examined the histone modification status of the endothelial marker genes KDR, von Willebrand factor (vWF), and vascular endothelial-cadherin (VE-cadherin) promoter regions. We observed that H3K27me3 was highly enriched at all 3 promoters studied in both PACs and CD34 ϩ cells ( Figure 3A ). The repressive H3K9me3 mark was also detected at the KDR promoter in PACs and CD34 ϩ cells, although at a lower level. The levels of histone H3 acetylation marks were higher at the VEcadherin promoter in PACs and the vWF and VE-cadherin promoter in CD34 ϩ cells ( Figure 3A ). The active H3K4me3 mark was overall rather low. In contrast, in differentiated endothelial cells, active marks are dominant ( Figure 3A) . Interestingly, the active H3K4me3 was higher than the histone H3 acetylation at the KDR, vWF, and VE-cadherin promoter and positive regulatory domains I/II of eNOS promoter in endothelial cells (Figure 2A and 3A) . Despite active histone H3 acetylation marks at some promoters ( Figure 3A) , the mRNA expression levels of KDR, vWF, and VE-cadherin are very low in PACs and CD34 ϩ cells compared to HUVEC ( Figure 3B ) indicating that silencing H3K27me3 plays a dominant role in repressing gene expression of these endothelial genes.
Increased Expression of eNOS in Proangiogenic Cells After DZNep and Trichostatin A Treatment
Because the promoters of all endothelial committed genes are characterized by high repressive H3K27me3 in PACs and CD34 ϩ cells, we determined whether inhibition of this repressive histone modification might facilitate endothelial lineage commitment. Therefore, we treated PACs with 3-deazaneplanocin A (DZNep), an S-adenosylhomocysteine hydrolase inhibitor, which inhibits Ezh2 and acts as an inhibitor of H3K27 trimethylation. 16 DZNep dosedependently reduced overall H3K27me3 levels as shown by Western blot and inhibited H3K27me3 at the eNOS promoter ( Figure 4A and 4C ). However, eNOS mRNA expression remained low and was not influenced by DZNep treatment despite the efficient reduction of the silencing marks (Supplemental Figure IIA and Figure 4C ). Because eNOS expression also requires active histone acetylation, 17 we next combined DZNep with the histone deacetylase inhibitor Trichostatin A (TSA). Indeed, the combination of DZNep and TSA modestly increased histone H3 acetylation and signifi- cantly increased eNOS mRNA expression in PACs ( Figure  4B and 4D). The activation of the eNOS promoter was further confirmed by ChIP experiments showing that DZNep/TSA treatment increased the binding of the eNOS activating transcription factor Sp1 to the regulatory region of the eNOS promoter ( Figure 4E ). Interestingly, DZNep treatment alone significantly increased eNOS expression in CD34 ϩ cells and the combination of DZNep and TSA induced a further augmentation of eNOS that exceeds the response of PACs (PACs: 1.4-fold increase; CD34 ϩ cells: 9.2-fold increase). In contrast, DZNep and TSA did not increase but even reduced eNOS expression in differentiated cells such as HUVEC or smooth muscle cells (SMCs) (Supplemental Figure IIB) suggesting a cell type-specific response to these pharmacological modulators. Together, our data suggest that the reduction of repressive H3K27me3 marks in combination with pharmacological augmentation of histone H3 acetylation can derepress the eNOS promoter in proangiogenic cells.
Hypoxia Increases the Balance of Active Versus Repressive Histone Marks at Endothelial Promoters
Among the many environmental signals in ischemic tissue, hypoxia is one of the strongest stimuli to enhance recruitment of progenitor cells and induce angiogenesis. Therefore, we investigated whether hypoxia modulates epigenetic control mechanisms to sensitize PACs for endothelial differentiation. To address this question, we exposed PACs to a hypoxic environment (1% O 2 ) and analyzed the mRNA level of eNOS and KDR. Both eNOS and KDR mRNA expression were time-dependently upregulated by hypoxia ( Figure 5A ). In line with the increase mRNA expression, eNOS protein was upregulated in PACs after hypoxic stimulation (Supplemental Figure IIIA and IIIB) . In parallel, hypoxia significantly (PϽ0.01) reduced the overall levels of repressive histone H3K27me3 marks ( Figure 5B and 5C). Furthermore, H3K27me3 marks are significantly reduced at the eNOS promoter, and the ratio of active H3K4me3 to repressive H3K27me3 marks were increased at all sites of the eNOS promoter studied after exposure of the cells to hypoxia ( Figure 5D ). Similarly, hypoxia increased the ratio of active H3K4me3 versus repressive H3K27me3 marks at the KDR (393Ϯ103%), vWF (659Ϯ301%), and VE-cadherin (298Ϯ81%) promoters. These data suggest that hypoxia changes the epigenetic signatures toward an active state and, thereby, facilitates endothelial gene expression in PACs.
Hypoxia Upregulates the Expression of Demethylases
Because previous studies suggest that hypoxia can stimulate the expression of proteins that belong to the JmjC-domain family, 18 we specifically determined whether Jmjd3 and UTX, which both were shown to reverse H3K27me3 marks, are regulated. Indeed, Jmjd3 and UTX mRNA expression were time-dependently upregulated by hypoxia in vitro (Figure 6A ) and were increased in muscle tissue after induction of hind limb ischemia in vivo (9.1-fold in UTX and 10.2-fold in Jmjd3 at day 4). Consistent with the increase of mRNA expression, Jmjd3 protein and, to a minor extent, UTX protein levels were up-regulated after hypoxic stimulation of PACs ( Figure 6B ). To address whether Jmjd3 is recruited to the eNOS promoter, we further performed ChIP experiments. These experiments demonstrate that Jmjd3 is recruited to some sites at eNOS promoter ( Figure 6C ). Taken together, these data demonstrate that hypoxia-induced upregulation of the histone demethylase Jmjd3 parallels the reduction of repressive histone marks at the promoter of endothelial genes, indicating that hypoxia may epigenetically modulate endothelial commitment.
Silencing of Jmjd3 Induces Cell Death and Senescence
To investigate whether the increase of Jmjd3 expression indeed causally contributes to the hypoxia-induced expression of eNOS, we generated lentiviral vectors expressing short hairpin RNAs (shRNA) against Jmjd3. However, despite testing 5 different sequences, we only could reduce the level of Jmjd3 by about 35% in PACs and silencing of Jmjd3 was associated with an induction of apoptosis and an increased expression of senescence markers (p14 ARF, p16 INK, p21 Cip, and p53, Figure 7A through 7C) . Moreover, the combination of shJmjd3 and hypoxia resulted in the death of more than 30% of PACs indicating that Jmjd3 expression is essential for PAC survival. Therefore, we were unable to address the question whether Jmjd3 regulates eNOS expression in PACs. However, because previous studies demonstrated that in other cell types Jmjd3 might have a different effect on senescence, 19 we additionally evaluated the function of Jmjd3 in mesoangioblasts. In these cells, silencing of Jmjd3 did not affect survival and did not affect the expression of senescence marker genes (data not shown) allowing us to test the requirement of Jmjd3 for the hypoxia-induced regulation of eNOS. Indeed, silencing of Jmjd3 significantly reduced the hypoxia-induced increase in eNOS expression ( Figure 7D ).
Discussion
The data of the present study demonstrate that endothelial committed genes are epigenetically silenced in different subtypes of human EPCs including cultured PACs and isolated bone marrow-derived CD34 ϩ cells. Silencing of promoters of endothelial committed genes occurred at the level of DNA methylation and histone modifications. Partic- Figure 5 . Hypoxia up-regulated endothelial nitric oxide synthase (eNOS) gene expression and down-regulated H3K27me3 at the eNOS promoter. A, Quantitative eNOS, KDR mRNA levels in proangiogenic cells (PACs) exposed to hypoxia (1% O 2 ). The expression level of eNOS and KDR gene under normoxic condition was set as 1 and fold induction is shown. Data represents meansϮSEM, nϭ5 to 6. B, Western blot analysis of histone proteins in PAC exposed to hypoxia (1% O 2 ). Histone H3 is used as a loading control. C, Immunofluorescence image of H3K27me3 (pink) in PAC exposed to normoxia or hypoxia (1% O 2 ). Nuclei are stained in blue. Bars represent 20 m. D, Quantitative chromatin immunoprecipitation (ChIP) analysis of H3K27me3 (top), the ratio of active vs repressive chromatin marks (H3K4me3/H3K27me3, bottom) at the eNOS promoter locus in PAC exposed to normoxia or hypoxia for 36 hours. Data were expressed as % input as meansϮSEM. The enrichment level of H3K27me3 and the level of H3K4me3/ H3K27me3 under normoxic condition was set as 1 and fold induction is shown. nϭ6 to 12. *PϽ0.05.
ularly, H3K27me3 was prominent at all promoters studied (eNOS, KDR, vWF, and VE-cadherin) suggesting that the regulation of H3K27 methylation may play a crucial role in regulating endothelial commitment of adult progenitor cells. In addition, most of the promoters of endothelial committed genes lacked active histone marks that are typically required for active gene expression in PACs and CD34 ϩ cells. These data indicate that the cells studied are not (yet) determined to the endothelial lineage and that the induction of endothelial commitment may require epigenetic remodeling at the promoters of the endothelial lineage committed genes.
In order to reverse epigenetic silencing to facilitate commitment to an endothelial cell fate, we used a pharmacological approach to inhibit the methylation of H3K27, the silencing mark that was highest at the promoters of the EPCs. The pharmacological inhibitor DZNep thereby blocks the enzyme Ezh2, which catalyzes the trimethylation of H3K27. Although DZNep reduced the levels of overall H3K27me3 and the prevalence of H3K27me3 at the eNOS promoter, DZNep alone was not sufficient to augment eNOS expression in PACs. Because active H3 marks are necessary for eNOS expression in embryonic stem cells and DZNep exhibits some inhibitory effects on active histone marks (see Figure 4A ), we speculated that activating histone modifications may be required to support eNOS expression. Therefore, we combined DZNep with low concentrations of the histone deacetylase inhibitor TSA and indeed showed that the combination of the substances facilitates eNOS expression. Of note, these effects were dose-dependent and higher concentration of TSA and DZNep were exhibiting toxic effects and even suppressed eNOS expression. This finding is consistent with previous data showing that the complete blockade of histone deacetylases reduces eNOS levels in EPCs. 6 Interestingly, the derepression of eNOS was cell-type specific. In CD34 ϩ cells, DZNep alone significantly induced eNOS expression and the combination of DZNep and TSA further increased to levels much higher compared to PACs, whereas in HUVEC and SMC no increase in eNOS expression was seen. These data indicate that CD34 ϩ cells (and PACs) are sensitive to the derepression of the eNOS promoter by pharmacological inhibition of the methyltransferase Ezh2. Consistently, the expression of Ezh2 was higher in CD34 ϩ cells and PACs compared to HUVEC and SMC (Supplemental Figure IIC) . However, the increases in eNOS expressionalthough significant-were only modest and the levels achieved under optimal dosing of both inhibitors in PACs and CD34 ϩ cells were not comparable to that of HUVEC. These findings are consistent with a remaining DNA methylation of the eNOS promoter observed in PACs after incubation with DZNep and TSA (Supplemental Figure V) . Therefore, the removal of silencing histone marks is not sufficient to induce a DNA demethylation of the eNOS promoter within a few days. Because it is known that DNA methylation, particularly of promoters with low CpG island content (as the eNOS promoter), does not fully block transcriptional activation, 20 the removal of silencing histone modification and increase of activating histone marks may be sufficient to partially activate the eNOS promoter.
In the second part of the article, we evaluated the influence of physiological factors that may modify the epigenetic signatures of PACs. Because hypoxia plays a critical role in recruiting proangiogenic cells, we specifically determined the effect of hypoxia. Hypoxia indeed increased the expression of eNOS and KDR and altered histone modifications. Thereby, the silencing H3K27me3 mark was significantly reduced by hypoxia as shown by Western blotting and as confirmed by immunohistochemistry and ChIP of the eNOS promoter. In addition, hypoxia increased the levels of active histone marks. These findings are consistent with data from others showing that hypoxia improves EPC functions 21 and activates Figure 6 . Hypoxia up-regulated the expression of demethylases. A, Quantitative Jmjd3 and UTX mRNA levels in PACs exposed to hypoxia (1% O 2 ). Data represents meansϮSEM, nϭ5 to 6. B, Western blot analysis of JmjC-domain protein levels in PAC exposed to hypoxia. ␤-actin is used as a loading control. C, Quantitative chromatin immunoprecipitation (ChIP) analysis of Jmjd3 at the eNOS promoter locus in proangiogenic cells (PACs) exposed to normoxia or hypoxia for 36 hours. Data were expressed as % input as meansϮSEM. The enrichment level of Jmjd3 under normoxic condition was set as 1 and fold induction is shown. nϭ6 to 7. *PϽ0.05. eNOS expression in endothelial cells. 22 However, a recent study reported that hypoxia reduces histone H3 acetylation and represses eNOS in endothelial cells 23 via sustained hypoacetylation at the eNOS promoter leadings to decreased nucleosome accessibility. Consistent with this study, in HUVEC histone acetylation (histone H3) at the proximal eNOS promoter marginally decreased on hypoxia, whereas in PACs histone acetylation at the eNOS promoter did not decrease on hypoxia (data not shown). Beyond that, hypoxia did not increase Jmjd3 expression and did not decrease H3K27me3 marks in HUVEC (Supplemental Figure IV) . The reason for this discrepant reaction and the precise mechanisms regulating Jmjd3 recruitment is unclear but may be due to the different cell types used in the studies (mature endothelial cells versus progenitor cell populations). Indeed, EPCs and HUVEC are reported to display different responses to hypoxia. Whereas hypoxia induced an increased proliferation in EPCs, a proliferation arrest was induced in HUVEC. 21, 24 The mechanisms by which hypoxia modulates histone modifications are not entirely solved but may include the upregulation of histone demethylases of the JmjC-domain containing family. Indeed, Jmjd3 mRNA and protein was significantly increased by hypoxia and recruited to the eNOS promoter. However, when we attempted to study the causal involvement of Jmjd3 in hypoxia-mediated upregulation of eNOS, we observed that Jmjd3 silencing lead to induction of apoptosis and senescence in PACs, which precluded testing the original hypothesis. The induction of apoptosis and senescence in PACs by Jmjd3 silencing was surprising because it has been reported that Jmjd3 can induce oncogene-mediated senescence in cancer cells. 19 However, Jmjd3 was recently shown to have an essential function in myeloid cells. 25 Because PACs resemble monocytic cells, our observation may be related to a crucial role of Jmjd3 in this cell type. To address the principal role of hypoxia-mediated up-regulation of Jmjd3, we therefore used an alternative circulating cell, mesoangioblast, which does not express myeloid or hematopoietic markers. 14 Although mesoangioblasts also showed a high DNA methylation pattern of the eNOS promoter, eNOS expression was upregulated by hypoxia and this effect was prevented in the absence of Jmjd3. These results provide evidence that, in some cell types, Jmjd3 expression contributes to the regulation of the eNOS promoter on induction of hypoxia.
Together, the present study is the first to evaluate the epigenetic signature of promoters of endothelial committed genes in different subsets of cells that have been used to augment neovascularization. Our findings demonstrating an epigenetic repression of endothelial genes indicate that the cells studied are not predetermined to the endothelial lineage. This is consistent with previous reports showing that endothelial marker gene expression detected in PACs might be a consequence of transferred mRNA by contaminating cells, such as platelets, 26 as well as by the lack of direct differentiation of isolated hematopoietic stem cells to the endothelial lineage. 27 However, several other groups have shown that hematopoietic cells can acquire an endothelial cell fate. 2, 9, 28 Therefore, we cannot exclude that the different culture protocols might modify (or reprogram) the cells. Indeed, a combination of pharmacological substances as well as hypoxia changed the epigenetic signature indicating that modulation in the cell environment might potentially result in a change in cell fate.
